RVTY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revvity Inc (RVTY) is not a strong buy at the moment for a beginner investor seeking long-term growth. While the company has shown moderate financial growth and has a global presence in the health sciences sector, recent insider selling, analyst downgrades, and margin risks heading into Q1 make it prudent to hold off on investing until more clarity is available post-earnings release.
The technical indicators are neutral. The MACD is positive but contracting, RSI is neutral at 44.661, and moving averages are converging. The stock is trading near a key support level (S1: 86.897) with resistance at R1: 93.895. No clear upward momentum is indicated.
Revvity has a strong global presence, serves over 160 countries, and is part of the S&P 500 index. Revenue and net income have shown moderate growth YoY, and the company is hosting a Q1 earnings call soon, which could provide further insights.
Insiders have significantly increased selling activity (up 2763.40% over the last month). Analysts have downgraded the stock recently, citing margin risks and competitive threats. The stock's gross margin has declined YoY, and no recent congress trading data or influential figure activity supports a buy decision.
In Q4 2025, Revvity reported a 5.85% YoY revenue increase, 3.93% YoY net income growth, and an 11.54% YoY EPS increase. However, gross margin dropped by -3.38%, indicating potential cost pressures.
Recent analyst activity shows mixed to negative sentiment. Barclays downgraded the stock to Equal Weight with a reduced price target of $95, citing margin risks. JPMorgan also lowered its price target to $96 with a Neutral rating. While some analysts maintain positive ratings, the overall trend suggests caution.
